| scholarly article | Q13442814 |
| editorial | Q871232 |
| review article | Q7318358 |
| P356 | DOI | 10.1007/S00392-007-0486-Z |
| P698 | PubMed publication ID | 17294353 |
| P2093 | author name string | B Scheller | |
| P2860 | cites work | Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study | Q46842288 |
| Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. | Q53589461 | ||
| Effect of X-Ray Contrast Media on Blood Flow Properties after Coronary Angiography | Q62761035 | ||
| Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents | Q72827801 | ||
| Effect of haemodialysis after contrast medium administration in patients with renal insufficiency | Q74333878 | ||
| A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial | Q79443255 | ||
| Acute and subacute stent occlusion; risk-reduction by ionic contrast media | Q28176172 | ||
| Prophylaxis strategies for contrast-induced nephropathy | Q28247353 | ||
| Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine | Q33910096 | ||
| The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable | Q33975349 | ||
| N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up | Q33981981 | ||
| Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial | Q34176397 | ||
| N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. | Q34542789 | ||
| N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: a multicentre clinical trial | Q35584286 | ||
| Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature | Q35670852 | ||
| N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. | Q35673022 | ||
| Prophylaxis of iodinated contrast media-induced nephropathy: a pharmacological point of view | Q35742865 | ||
| Systematic review of the impact of N-acetylcysteine on contrast nephropathy | Q35746654 | ||
| N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis | Q36079414 | ||
| Effect of nonionic radiocontrast agents on the occurrence of contrast-induced nephropathy in patients with mild-moderate chronic renal insufficiency: pooled analysis of the randomized trials. | Q36145586 | ||
| Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. | Q36484244 | ||
| Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study | Q42278871 | ||
| Early and late reactions after the use of iopamidol 340, ioxaglate 320, and iodixanol 320 in cardiac catheterization. | Q43557938 | ||
| Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful | Q43826447 | ||
| Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). | Q43865327 | ||
| Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty | Q43873696 | ||
| Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure | Q43975017 | ||
| Acetylcysteine and contrast agent-associated nephrotoxicity | Q44054777 | ||
| Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy | Q44200953 | ||
| A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography | Q44213039 | ||
| Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC) | Q44221623 | ||
| Nephrotoxic effects in high-risk patients undergoing angiography | Q44305026 | ||
| Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast | Q44320971 | ||
| A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study | Q44487840 | ||
| The Prevention of Radiocontrast-Agent–Induced Nephropathy by Hemofiltration | Q44605354 | ||
| Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial | Q44643934 | ||
| Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography | Q44660125 | ||
| The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography | Q44665688 | ||
| Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography | Q44683769 | ||
| Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials | Q44719854 | ||
| Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial | Q44866576 | ||
| Absence of nephro-protective effect of acetylcysteine in patients with chronic renal failure investigated by coronary angiography | Q44974019 | ||
| A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect | Q45075926 | ||
| Effectiveness of acetylcysteine in prevention of contrast nephropathy | Q45248753 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 125-129 | |
| P577 | publication date | 2007-03-01 | |
| P1433 | published in | Clinical Research in Cardiology | Q2665050 |
| P1476 | title | How to protect from contrast media-induced nephropathy? | |
| P478 | volume | 96 |
| Q43256176 | Contrast medium induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. |
| Q57448723 | Impact of N-acetylcysteine on contrast-induced nephropathy defined by cystatin C in patients with ST-elevation myocardial infarction undergoing primary angioplasty |
| Q53441809 | Quality control after total arterial revascularisation: multislice computer tomography cannot replace coronary angiography. |
Search more.